Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP2-F6) - HRP - 50 µg

Primary Monoclonal Antibodies>Infectious Diseases|Monoclonal Antibodies|Recombinant Antibodies|SARS-CoV-2

Ships Overnight on Blue Ice

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 belongs to the Coronaviridae family, and its single-stranded, positive-sense RNA genome shares 79.6% identity with SARS-CoV1. The spike (S), envelope (E), membrane (M), and nucleocapsid proteins (N) are four essential structural proteins of SARS-CoV-22. The 46 kDa N protein is highly conserved and shares 90% homology with SARS-CoV3. Similar to SARS-CoV, SARS-CoV-2 has an N-terminal (NTD) and C-terminal domain (CTD), linked by a linker region. The NTD binds to RNA, while the CTD self-oligomerizes4, 5, aiding viral genome packaging into a helical ribonucleoprotein complex6. The N protein also participates in viral transcription, replication, and modulation of cell signaling pathways7, 8. Some vaccine and diagnostic assays9 have focused on the N protein as it is highly expressed during infection and activates antibodies3, 10 and memory T cells11, 12, found in convalescent sera. The N-protein also evades the innate immune system by inhibiting RNAi13, identifying it as a potential therapeutic target.

0.5 mg/ml

The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.

SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein, Monoclonal Antibody, COVID-19